Low Molecular weight Heparin has been the standard of care in venous thromboembolism (VTE) in patients with active cancer. Recent research suggests that the role of direct oral anticoagulants (DOACs) in this population.  Carrie discusses the findings from a randomized open-label trial of patients with active VTE receiving either dalteparin or rivaroxaban. Comparative discussion on outcomes  including VTE recurrence, major bleeding, and clinically relevant non-major bleeding.


cancer,antiphospholipid syndrome,VTE,rivaroxaban




Disease Condition ,Therapeutic Modality ,Coronary Artery Disease,Cancer and Heart,Pharmacotherapeutics,Coronary Artery Vasospasm,Myocardial Infarction,Ischemic Heart Disease,DCAN_others,Thrombolysis in Myocardial Infarction (TIMI) Score,TPHT_others